Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

SOUTH SAN FRANCISCO, Calif., March 11 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule therapeutics, today reported financial results for the quarter and fiscal year ended December 31, 2007.

Total revenue for the fourth quarter of 2007 was $2.0 million, with a net loss of $8.8 million. Total revenue for the year ended December 31, 2007 was $9.7 million, with a net loss of $38.8 million. As of December 31, 2007, cash, cash equivalents and marketable securities totaled $47.7 million, and debt totaled $2.3 million. Net cash used in operating activities in 2007 was $34.5 million.

Recent Highlights

-- This week at the 39th Annual Meeting on Women's Cancer hosted by the Society for Gynecologic Oncology in Tampa, Florida, Sunesis presented positive interim results from the company's ongoing Phase 2 clinical trial of SNS-595, a novel naphthyridine analog, in advanced platinum-resistant ovarian cancer patients.
-- Sixty-five women have been enrolled and treated with single-agent

SNS-595 at a dose of 48 mg/m2 administered once every three weeks,

with the majority of these women having been enrolled since October.

Forty-five women have sufficient follow up to yield useful safety

results and 35 are evaluable for best response using GOG-RECIST

criteria.

-- In this trial, SNS-595 has demonstrated disease control (defined as

stable disease, partial response or complete response), with 31 of

35 of evaluable patients having best responses of stable disease or

better. Of
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)...   Synthetic Biologics, Inc. (NYSE MKT: SYN), ... infections and diseases, announced today that the U.S. Patent ... for a composition of matter patent application that covers ... SYN-004. This is Synthetic Biologics, first allowed patent application ... to the Company,s extensive C. difficile patent ...
(Date:10/22/2014)... KONG , Oct. 22, 2014  aTyr Pharma ... that rare disease expert John C. McKew , ... McKew brings more than two decades of expertise in ... Institutes of Health, Wyeth Research and Genetics Institute, Inc. ... aTyr,s efforts to expand and translate its novel Physiocrine ...
(Date:10/20/2014)... 2014 Asterias Biotherapeutics, Inc. (NYSE MKT: ... a Notice of Grant Award (NGA) with the ... 1, 2014.  The NGA provides for the immediate ... of additional grant funds pursuant to the previously ... development of Asterias, product, AST-OPC1. The grant provides ...
(Date:10/20/2014)... Oct. 20, 2014 PureTech , a ... big healthcare problems, announced today the closing of ... participation from Invesco Perpetual, a $120 Billion group ... drive PureTech,s existing pipeline forward and to advance ... the scientific creativity to really go for the ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
... ... technology are highlighted at leading industry events. , ... Washington, DC (PRWEB) June 11, 2010 -- Open source software will be ... DIA Annual Meeting is the premier event for professionals involved in the discovery, ...
... June 11 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc.,(Nasdaq: CHBT ) ... products in China , today reported,its financial results for the ... , , 4Q10 Financial Highlights, ... year-over-year increase;, ...
... ... of the evolution of the influenza virus and its human host, post-graduate student Stephen Huff ... of safe, free software downloads - best of all, the service is free. , ... (PRWEB) June 5, 2010 -- We ...
Cached Biology Technology:Open Source Clinical Trials Software Featured at the 46th DIA Annual Meeting 2Open Source Clinical Trials Software Featured at the 46th DIA Annual Meeting 3China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 2China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 3China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 4China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 5China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 6China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 7China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 8China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 9China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 10China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 11China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 12China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 13China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 14China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 15China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 16Computational Microbiologist Uses His Expertise with Deadly Viruses to Devise a Superior System for Delivery of Safe, Free Software Downloads 2Computational Microbiologist Uses His Expertise with Deadly Viruses to Devise a Superior System for Delivery of Safe, Free Software Downloads 3Computational Microbiologist Uses His Expertise with Deadly Viruses to Devise a Superior System for Delivery of Safe, Free Software Downloads 4
(Date:10/19/2014)... access in India over the last 30 years ... emissions growth during that time, according to a ... Climate Change ., "Energy access is fundamental to ... life, including education, communication, and health," says IIASA ... While increased energy access is widely agreed to ...
(Date:10/18/2014)... patients referred for evaluation of suspected genetic conditions, ... 25 percent, including detection of a number of ... disease, according to a study appearing in ... coincide with the American Society of Human Genetics ... or coding regions of thousands of genes simultaneously ...
(Date:10/17/2014)... – Accurate knowledge regarding Ebola is critical and pertinent ... of hazardous global outbreak and epidemic. The Journal, ... a special issue, Ebola Virus and Public Health, to ... knowledge in this critical societal moment. , On ... Ebola for Clinicians . The primer was prepared by ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Whole-exome sequencing shows potential as diagnostic tool 2
... Director of Genomic Technologies, Dr Yijun RUAN, led a ... how genes interact/communicate and influence each other, even when ... discovery is crucial in understanding how human genes work ... and coordination takes place in human cells. The ...
... Spotted salamanders exposed to contaminated roadside ponds are ... paper in Scientific Reports. This study provides the first ... negative effects of roads apparently by evolving rapidly. ... a host of contaminants from road runoff. Chief among ...
... The first study to check the effects of eating ... small helpings of purple potatoes (Purple Majesty) a day decreases ... In a report in the ACS, Journal of Agricultural ... seemingly small, is sufficient to potentially reduce the risk of ...
Cached Biology News:Singapore scientists lead in 3D mapping of human genome to help understand human diseases 2Road runoff spurring spotted salamander evolution 2
This buffer is Specifically formulated to be used with Endogen's Poly-HRP Streptavidin...
... Microarray Gene Frame® has been specifically ... frames feature the same dual strength ... Frame® range for easy removal after ... and there are three sizes available. ...
For microscopy...
... slide processing offering reproducibility, reliability and ... miniaturization, automation and massive parallel analysis ... with many applications in both industrial ... from gene expression profiling, gene regulation ...
Biology Products: